Caribou Biosciences Cuts Workforce, Shifts Pipeline to Focus on Key Oncology Programs

Dow Jones

2025/04/25

By Kelly Cloonan

Caribou Biosciences plans to trim its workforce and shift its pipeline as it looks to focus on its lead oncology programs.

The Berkeley, Calif.-biopharmaceutical company on Thursday said it plans to reduce its workforce by about 32%. Such cuts would amount to roughly 47 employees, based on the total workforce of 147 full-time employees according to its latest annual filing.

The company is also discontinuing preclinical research as well as Phase 1 trials of treatments for lupus and relapsed or refractory acute myeloid leukemia.

Caribou Biosciences expects cash payments from the workforce reduction and strategic pipeline prioritization to total $2.5 million to $3.5 million.

The changes will extend Caribou's cash runway by one year, funding the current operating plan into the second half of 2027, it said.

Write to Kelly Cloonan at kelly.cloonan@wsj.com

(END) Dow Jones Newswires

April 24, 2025 17:08 ET (21:08 GMT)

應版權方要求，你需要登入查看該內容

登入 / 註冊

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2530539999"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2530539999\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2530539999?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-04-25 05:08","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2530539999","market":"other","top_or_hot":-1,"title":"Caribou Biosciences Cuts Workforce, Shifts Pipeline to Focus on Key Oncology Programs","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Kelly Cloonan \n</p>\n<pre>\n \n</pre>\n<p>\n  <a href=\"https://laohu8.com/S/CRBU\">Caribou Biosciences</a> plans to trim its workforce and shift its pipeline as it looks to focus on its lead oncology programs. \n</p>\n<p>\n  The Berkeley, Calif.-biopharmaceutical company on Thursday said it plans to reduce its workforce by about 32%. Such cuts would amount to roughly 47 employees, based on the total workforce of 147 full-time employees according to its latest annual filing. \n</p>\n<p>\n  The company is also discontinuing preclinical research as well as Phase 1 trials of treatments for lupus and relapsed or refractory acute myeloid leukemia. \n</p>\n<p>\n  Caribou Biosciences expects cash payments from the workforce reduction and strategic pipeline prioritization to total $2.5 million to $3.5 million. \n</p>\n<p>\n  The changes will extend Caribou's cash runway by one year, funding the  current operating plan into the second half of 2027, it said. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Kelly Cloonan at kelly.cloonan@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  April 24, 2025 17:08 ET (21:08 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Caribou Biosciences Cuts Workforce, Shifts Pipeline to Focus on Key Oncology Programs</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCaribou Biosciences Cuts Workforce, Shifts Pipeline to Focus on Key Oncology Programs\n</h2>\n<h4 class=\"meta\">\n<div class=\"head\" \">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time smaller\">2025-04-25 05:08</p>\n</div>\n</div>\n</h4>\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Kelly Cloonan \n</p>\n<pre>\n \n</pre>\n<p>\n  <a href=\"https://laohu8.com/S/CRBU\">Caribou Biosciences</a> plans to trim its workforce and shift its pipeline as it looks to focus on its lead oncology programs. \n</p>\n<p>\n  The Berkeley, Calif.-biopharmaceutical company on Thursday said it plans to reduce its workforce by about 32%. Such cuts would amount to roughly 47 employees, based on the total workforce of 147 full-time employees according to its latest annual filing. \n</p>\n<p>\n  The company is also discontinuing preclinical research as well as Phase 1 trials of treatments for lupus and relapsed or refractory acute myeloid leukemia. \n</p>\n<p>\n  Caribou Biosciences expects cash payments from the workforce reduction and strategic pipeline prioritization to total $2.5 million to $3.5 million. \n</p>\n<p>\n  The changes will extend Caribou's cash runway by one year, funding the  current operating plan into the second half of 2027, it said. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Kelly Cloonan at kelly.cloonan@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  April 24, 2025 17:08 ET (21:08 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2530539999","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2530539999","pubTimestamp":1745528880,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Caribou Biosciences plans to trim its workforce and shift its pipeline as it looks to focus on its lead oncology programs.The Berkeley, Calif.-biopharmaceutical company on Thursday said it plans to reduce its workforce by about 32%. Such cuts would amount to roughly 47 employees, based on the total workforce of 147 full-time employees according to its latest annual filing.The company is also discontinuing preclinical research as well as Phase 1 trials of treatments for lupus and relapsed or refractory acute myeloid leukemia.Caribou Biosciences expects cash payments from the workforce reduction and strategic pipeline prioritization to total $2.5 million to $3.5 million.The changes will extend Caribou's cash runway by one year, funding the  current operating plan into the second half of 2027, it said.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","CRBU":"Caribou Biosciences","BK4539":"次新股"},"translate_title":"Caribou Biosciences裁员，将产品线转移到关键肿瘤学项目","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CRBU":1},"content_text":"By Kelly Cloonan \n\n\n \n\n\nCaribou Biosciences plans to trim its workforce and shift its pipeline as it looks to focus on its lead oncology programs. \n\n\n  The Berkeley, Calif.-biopharmaceutical company on Thursday said it plans to reduce its workforce by about 32%. Such cuts would amount to roughly 47 employees, based on the total workforce of 147 full-time employees according to its latest annual filing. \n\n\n  The company is also discontinuing preclinical research as well as Phase 1 trials of treatments for lupus and relapsed or refractory acute myeloid leukemia. \n\n\n  Caribou Biosciences expects cash payments from the workforce reduction and strategic pipeline prioritization to total $2.5 million to $3.5 million. \n\n\n  The changes will extend Caribou's cash runway by one year, funding the  current operating plan into the second half of 2027, it said. \n\n\n \n\n\n  Write to Kelly Cloonan at kelly.cloonan@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  April 24, 2025 17:08 ET (21:08 GMT)\n\n\n  Copyright (c) 2025 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}